Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BHSTNASDAQ:EGRXNASDAQ:SAVANASDAQ:VIRI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSTBioHarvest Sciences$6.88-1.1%$6.16$4.66▼$7.38$113.00M0.816,819 shs3,013 shsEGRXEagle Pharmaceuticals$2.20+4.8%$1.77$1.50▼$2.30$28.57M0.8310,152 shs6,244 shsSAVACassava Sciences$2.11-2.1%$1.67$1.15▼$42.20$101.69M-23.00 million shs456,034 shsVIRIVirios Therapeutics$5.34-4.6%$4.79$0.13▼$1.04$102.84M1.581.05 million shs51,543 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSTBioHarvest Sciences+4.98%+9.61%+9.26%+34.10%+695,999,900.00%EGRXEagle Pharmaceuticals+6.33%+10.53%+6.60%+98.11%-40.68%SAVACassava Sciences-0.46%+2.38%+34.38%-23.76%-89.78%VIRIVirios Therapeutics+6.26%-1.75%+11.55%+25.84%+2,366.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHSTBioHarvest SciencesN/AN/AN/AN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASAVACassava Sciences3.7858 of 5 stars3.31.00.04.73.10.01.3VIRIVirios Therapeutics0.4111 of 5 stars1.30.00.00.02.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHSTBioHarvest Sciences 3.00Buy$13.6798.64% UpsideEGRXEagle Pharmaceuticals 0.00N/AN/AN/ASAVACassava Sciences 2.50Moderate Buy$54.502,489.07% UpsideVIRIVirios Therapeutics 2.50Moderate Buy$3.00-43.82% DownsideCurrent Analyst Ratings BreakdownLatest EGRX, BHST, SAVA, and VIRI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025BHSTBioHarvest SciencesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/8/2025BHSTBioHarvest SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/25/2025SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHSTBioHarvest Sciences$27.70M4.08N/AN/A($1.08) per share-6.37EGRXEagle Pharmaceuticals$257.55M0.11$5.50 per share0.40N/A∞SAVACassava SciencesN/AN/AN/AN/A$3.26 per shareN/AVIRIVirios TherapeuticsN/AN/AN/AN/A$0.20 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHSTBioHarvest Sciences-$12.56M-$0.50N/AN/AN/A-76.65%N/A-85.16%8/14/2025 (Estimated)EGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/ASAVACassava Sciences-$97.22M-$1.50N/AN/AN/AN/A-88.05%-64.98%8/14/2025 (Estimated)VIRIVirios Therapeutics-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%8/6/2025 (Estimated)Latest EGRX, BHST, SAVA, and VIRI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025BHSTBioHarvest Sciences-$0.15-$0.13+$0.02-$0.13$8.93 million$7.64 million5/8/2025Q1 2025SAVACassava SciencesN/A-$0.48N/A-$0.48N/AN/A3/31/2025Q4 2024BHSTBioHarvest Sciences-$0.12-$0.17-$0.05-$0.17$7.24 million$7.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHSTBioHarvest SciencesN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/AVIRIVirios TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHSTBioHarvest SciencesN/A0.800.48EGRXEagle PharmaceuticalsN/AN/AN/ASAVACassava SciencesN/A3.553.55VIRIVirios TherapeuticsN/A7.277.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHSTBioHarvest SciencesN/AEGRXEagle Pharmaceuticals85.36%SAVACassava Sciences38.05%VIRIVirios Therapeutics9.05%Insider OwnershipCompanyInsider OwnershipBHSTBioHarvest SciencesN/AEGRXEagle Pharmaceuticals28.90%SAVACassava Sciences2.40%VIRIVirios Therapeutics12.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHSTBioHarvest SciencesN/A16.43 millionN/AN/AEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataSAVACassava Sciences3048.31 million43.78 millionOptionableVIRIVirios Therapeutics519.26 million16.91 millionOptionableEGRX, BHST, SAVA, and VIRI HeadlinesRecent News About These CompaniesVirios Therapeutics (NASDAQ:VIRI) Shares Down 2.1% - Time to Sell?June 3 at 3:16 AM | marketbeat.comVirios Therapeutics (NASDAQ:VIRI) Stock Price Down 1.5% - Time to Sell?May 12, 2025 | marketbeat.comDogwood Therapeutics Inc (DWTX)March 16, 2025 | investing.comDogwood prices 578,950 shares at $8.26 in registered direct offeringMarch 13, 2025 | markets.businessinsider.comDogwood announces conversion of existing $19.5M in debt to equityMarch 12, 2025 | markets.businessinsider.comDWTX Stock trading resumesFebruary 11, 2025 | markets.businessinsider.comDogwood Therapeutics, Inc. (DWTX)February 2, 2025 | finance.yahoo.comDWTX Stock trading halted, volatility trading pauseJanuary 28, 2025 | markets.businessinsider.comDWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly GrowthJanuary 23, 2025 | msn.comDogwood announces first patient dosed in Phase 2b trial on HalneuronJanuary 22, 2025 | markets.businessinsider.comPolluted communities hold their breath as companies struggle with California’s diesel truck banDecember 10, 2024 | apnews.comDogwood Therapeutics faces potential Nasdaq delistingNovember 24, 2024 | uk.investing.comDogwood says low-dose IMC-2 treatment reduces long-COVID fatigueNovember 18, 2024 | markets.businessinsider.comDogwood Study Finds IMC-2 Treatment Reduces Long-COVID Related Fatigue, Sleep DisturbanceNovember 18, 2024 | markets.businessinsider.comInovio Pharmaceuticals (NASDAQ:INO) Stock Quotes, Forecast and News SummaryNovember 16, 2024 | benzinga.comDWTX: Phase 2 Long COVID Results Expected SoonNovember 12, 2024 | msn.comBuy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst ConfidenceNovember 10, 2024 | markets.businessinsider.comDogwood Therapeutics Reports Q3 2024 Financial ResultsNovember 9, 2024 | markets.businessinsider.comDogwood Therapeutics Announces Third Quarter 2024 Financial ResultsNovember 8, 2024 | markets.businessinsider.comDogwood Therapeutics, Inc.: Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementOctober 31, 2024 | finanznachrichten.deDogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementOctober 30, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEGRX, BHST, SAVA, and VIRI Company DescriptionsBioHarvest Sciences NASDAQ:BHST$6.88 -0.08 (-1.15%) As of 03:27 PM EasternBioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Eagle Pharmaceuticals NASDAQ:EGRX$2.20 +0.10 (+4.76%) As of 03:06 PM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Cassava Sciences NASDAQ:SAVA$2.10 -0.05 (-2.09%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Virios Therapeutics NASDAQ:VIRI$5.34 -0.26 (-4.64%) As of 06/4/2025Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Guidewire Rockets Higher: A Move Above $300 Is Probable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
